The domestic stock market has shown a strong rebound, overcoming the shock of the previous day's plunge, with investor sentiment recovering rapidly to the extent of triggering a buy-side circuit breaker for the KOSPI. Amid this, buying pressure has flowed in, centered on large-cap pharmaceutical and biotech stocks, showing a strong upward trend across the industry.

As of the morning of the 9th, Alteogen recorded 327,000 won, soaring 12.95% compared to the previous trading day. During the session, it rose to 340,000 won, leading the upward momentum in the pharmaceutical and biotech sectors. Centered on large-cap stocks, Celltrion rose 6.34% (169,500 won), Green Cross 6.15% (126,000 won), Dong-A ST 6.32%, Hanmi Pharmaceutical 4.12%, and Hanall Biopharma 5.36%.

Mid- and small-cap pharmaceutical stocks also showed a strong trend. Bionex rose 7.87%, Prestige Biopharma 7.31%, ISU Abxis 6.72%, Celltrion Pharmaceuticals 6.17%, and Boryung 5.18%, while Samchundang Pharmaceutical also continued its upward trend, rising 1.05% to 241,500 won.

The strength of pharmaceutical stocks on this day is interpreted as the result of the revival of a preference for growth stocks along with the overall market rebound. It is analyzed that as the investment sentiment, which had contracted due to the global stock market plunge the previous day, recovered, funds flowed into pharmaceutical and biotech companies with technological prowess and growth potential.

The market has assessed that the expansion of the global pharmaceutical market and the intensifying competition in biosimilars and new drug development could have a positive impact on the domestic pharmaceutical industry. Expectations for global market expansion were highlighted for companies like Celltrion and Samsung Epis Holdings, while the growth potential of Alteogen and Hanmi Pharmaceutical was noted based on their technological competitiveness.

The securities industry believes that the research and development (R&D)-focused pharmaceutical and biotech sectors could see relative benefits in a phase where the burden of interest rates is easing. However, there is also an analysis that stock-by-stock approach is necessary, as the volatility of individual stocks could expand depending on clinical trial results, technology exports, and licensing progress, due to the characteristics of the industry.

Going forward, domestic investors are expected to monitor the trends of the global pharmaceutical market, the R&D achievements of major companies, and the expansion of overseas operations while watching the flow of pharmaceutical stocks.

[This article was written based on publicly available market data and official materials, and artificial intelligence (AI) was utilized in the process of drafting the article and organizing the information. The information provided in this article is for general investment information purposes and does not constitute a solicitation to invest in any specific stock or financial product. Investing in the stock and financial markets carries the risk of principal loss, and all responsibility for investment lies with the investor. Please be sure to check related disclosures and official materials before making investment decisions. This publication does not bear any legal or financial responsibility for the aforementioned information.]